-
1
-
-
79952515201
-
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
-
Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105-113.
-
(2011)
J Clin Lipidol
, vol.5
, pp. 105-113
-
-
Otvos, J.D.1
Mora, S.2
Shalaurova, I.3
Greenland, P.4
Mackey, R.H.5
Goff, D.C.6
-
2
-
-
84874949110
-
Update on the detection and treatment of atherogenic low-density lipoproteins
-
Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20:140-147.
-
(2013)
Curr Opin Endocrinol Diabetes Obes
, vol.20
, pp. 140-147
-
-
Sniderman, A.1
Kwiterovich, P.O.2
-
3
-
-
0037603589
-
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
-
Abifadel M, Varret M, Rabés JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
-
(2003)
Nat Genet
, vol.34
, pp. 154-156
-
-
Abifadel, M.1
Varret, M.2
Rabés, J.P.3
Allard, D.4
Ouguerram, K.5
Devillers, M.6
Cruaud, C.7
Benjannet, S.8
Wickham, L.9
Erlich, D.10
Derré, A.11
Villéger, L.12
Farnier, M.13
Beucler, I.14
Bruckert, E.15
Chambaz, J.16
Chanu, B.17
Lecerf, J.M.18
Luc, G.19
Moulin, P.20
Weissenbach, J.21
Prat, A.22
Krempf, M.23
Junien, C.24
Seidah, N.G.25
Boileau, C.26
more..
-
5
-
-
34247605063
-
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
-
Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Mansour MN, McGrath KM, Seddon AP, Shenolikar S, Stutzman-Engwall KJ, Warren LC, Xia D, Qiu X. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14:413-419.
-
(2007)
Nat Struct Mol Biol
, vol.14
, pp. 413-419
-
-
Cunningham, D.1
Danley, D.E.2
Geoghegan, K.F.3
Griffor, M.C.4
Hawkins, J.L.5
Subashi, T.A.6
Varghese, A.H.7
Ammirati, M.J.8
Culp, J.S.9
Hoth, L.R.10
Mansour, M.N.11
McGrath, K.M.12
Seddon, A.P.13
Shenolikar, S.14
Stutzman-Engwall, K.J.15
Warren, L.C.16
Xia, D.17
Qiu, X.18
-
6
-
-
33645103550
-
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
-
Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
-
(2006)
N Engl J Med
, vol.354
, pp. 1264-1272
-
-
Cohen, J.C.1
Boerwinkle, E.2
Mosley, T.H.3
Hobbs, H.H.4
-
7
-
-
84942104125
-
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
-
Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36:2415-2424.
-
(2015)
Eur Heart J
, vol.36
, pp. 2415-2424
-
-
Shimada, Y.J.1
Cannon, C.P.2
-
9
-
-
85006201116
-
Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy
-
Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015;4:e002224 doi: 10.1161/JAHA.115.002224.
-
(2015)
J Am Heart Assoc
, vol.4
-
-
Koren, M.J.1
Kereiakes, D.2
Pourfarzib, R.3
Winegar, D.4
Banerjee, P.5
Hamon, S.6
Hanotin, C.7
McKenney, J.M.8
-
10
-
-
84862219022
-
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
-
McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 2344-2353
-
-
McKenney, J.M.1
Koren, M.J.2
Kereiakes, D.J.3
Hanotin, C.4
Ferrand, A.C.5
Stein, E.A.6
-
11
-
-
84976897420
-
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
-
Xu RX, Li S, Zhang Y, Li XL, Guo YL, Zhu CG, Li JJ. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 2014;13:188.
-
(2014)
Lipids Health Dis
, vol.13
, pp. 188
-
-
Xu, R.X.1
Li, S.2
Zhang, Y.3
Li, X.L.4
Guo, Y.L.5
Zhu, C.G.6
Li, J.J.7
-
12
-
-
84939424952
-
Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter?
-
Phillips CM, Perry IJ. Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter? Atherosclerosis. 2015;242:399-406.
-
(2015)
Atherosclerosis
, vol.242
, pp. 399-406
-
-
Phillips, C.M.1
Perry, I.J.2
-
13
-
-
65549116032
-
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia
-
Le May C, Kourimate S, Langhi C, Chétiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684-690.
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, pp. 684-690
-
-
Le May, C.1
Kourimate, S.2
Langhi, C.3
Chétiveaux, M.4
Jarry, A.5
Comera, C.6
Collet, X.7
Kuipers, F.8
Krempf, M.9
Cariou, B.10
Costet, P.11
-
14
-
-
35848940724
-
The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes
-
Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115:477-482.
-
(2007)
Exp Clin Endocrinol Diabetes
, vol.115
, pp. 477-482
-
-
Rizzo, M.1
Rini, G.B.2
Berneis, K.3
-
15
-
-
84864270750
-
Extendedrelease niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus
-
Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM. Extendedrelease niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord. 2012;10:260-266.
-
(2012)
Metab Syndr Relat Disord
, vol.10
, pp. 260-266
-
-
Bays, H.1
Giezek, H.2
McKenney, J.M.3
O'Neill, E.A.4
Tershakovec, A.M.5
-
16
-
-
84904252744
-
Effects of extended-release niacin with laropiprant in high-risk patients
-
HSP2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.
-
(2014)
N Engl J Med
, vol.371
, pp. 203-212
-
-
Landray, M.J.1
Haynes, R.2
Hopewell, J.C.3
Parish, S.4
Aung, T.5
Tomson, J.6
Wallendszus, K.7
Craig, M.8
Jiang, L.9
Collins, R.10
Armitage, J.11
-
17
-
-
77955046691
-
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients
-
Chan DC, Hamilton SJ, Rye KA, Chew GT, Jenkins AJ, Lambert G, Watts GF. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab. 2010;12:752-756.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 752-756
-
-
Chan, D.C.1
Hamilton, S.J.2
Rye, K.A.3
Chew, G.T.4
Jenkins, A.J.5
Lambert, G.6
Watts, G.F.7
-
18
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
Erratum in: N Engl J Med. 2010;362:1748
-
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. Erratum in: N Engl J Med. 2010;362:1748.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse, J.R.4
Leiter, L.A.5
Linz, P.6
Friedewald, W.T.7
Buse, J.B.8
Gerstein, H.C.9
Probstfield, J.10
Grimm, R.H.11
Ismail-Beigi, F.12
Bigger, J.T.13
Goff, D.C.14
Cushman, W.C.15
Simons-Morton, D.G.16
Byington, R.P.17
|